This pathway is expressed in tumour-associated macrophages and CAF, leading to the upregulation of PDL1 expression in tumoural cells along with an increase in Lymphocyte-activation gene 3 (LAG3), conferring resistance to anti-PDL1-based therapies [40]. This evidence concerns the gene LAG3 and neoplasm.